Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Works in Cardiovascular · Dermatology · GI & liver · Hematology · Immunology · Metabolic & endocrine · Oncology · Renal & urogenital · Respiratory · Women's health
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. is a clinical trial sponsor. It has 3 active clinical trials with 355 planned participants, across 10 therapeutic areas.
Trial track record · since 2021
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 355 planned participants, in Cardiovascular, Dermatology, GI & liver, Hematology and other areas. Since 2021 it has completed 0 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-08-13.
Approve Suite is not affiliated with Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.